Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (61-70 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|November 17, 2010
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexateMichael E Weinblatt, Edward C Keystone, Marc D Cohen, et al.
Arthritis Research & Therapy|January 12, 2005
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritisYuji Yamanishi, David L Boyle, Douglas R Green, et al.
The Journal of Rheumatology|September 3, 2011
Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogressionAlvin F Wells, Rene Westhovens, Diane Moniz Reed, et al.
Arthritis and Rheumatism|July 13, 2002
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trialE William St Clair, Carrie L Wagner, Adedigbo A Fasanmade, et al.
Rheumatology (Oxford, England)|September 13, 2015
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritisEdward C Keystone, Janet E Pope, J Carter Thorne, et al.
The Journal of Rheumatology|October 5, 2010
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIERDésirée van der Heijde, Ferdinand C Breedveld, Arthur Kavanaugh, et al.
The Journal of Rheumatology|December 1, 2004
Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanerceptBoulos Haraoui, Edward C Keystone, J Carter Thorne, et al.
The Journal of Rheumatology|May 17, 2011
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson, Allan Gibofsky, William R Palmer, et al.
Rheumatology International|June 8, 2013
Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative studyOmer Nuri Pamuk, Bunyamin Kisacik, Gulsum Emel Pamuk, et al.
The Journal of Rheumatology|July 3, 2019
Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI RegistriesEdward C Keystone, Emmanouil Rampakakis, Mohammad Movahedi, et al.
Pageof 16

Showing results (61-70 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|November 17, 2010
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexateMichael E Weinblatt, Edward C Keystone, Marc D Cohen, et al.
Arthritis Research & Therapy|January 12, 2005
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritisYuji Yamanishi, David L Boyle, Douglas R Green, et al.
The Journal of Rheumatology|September 3, 2011
Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogressionAlvin F Wells, Rene Westhovens, Diane Moniz Reed, et al.
Arthritis and Rheumatism|July 13, 2002
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trialE William St Clair, Carrie L Wagner, Adedigbo A Fasanmade, et al.
Rheumatology (Oxford, England)|September 13, 2015
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritisEdward C Keystone, Janet E Pope, J Carter Thorne, et al.
The Journal of Rheumatology|October 5, 2010
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIERDésirée van der Heijde, Ferdinand C Breedveld, Arthur Kavanaugh, et al.
The Journal of Rheumatology|December 1, 2004
Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanerceptBoulos Haraoui, Edward C Keystone, J Carter Thorne, et al.
The Journal of Rheumatology|May 17, 2011
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson, Allan Gibofsky, William R Palmer, et al.
Rheumatology International|June 8, 2013
Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative studyOmer Nuri Pamuk, Bunyamin Kisacik, Gulsum Emel Pamuk, et al.
The Journal of Rheumatology|July 3, 2019
Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI RegistriesEdward C Keystone, Emmanouil Rampakakis, Mohammad Movahedi, et al.
Pageof 16